[[Whitepaper]] Development of Robust Processes for Large Scale Antibody-Drug Conjugation

Antibody-drug Conjugates (ADCs) represent a potent therapeutic for targeted delivery of toxins to specific cell types. ADCs are composed of a moncolonal antibody (mAb) conjugated to a drug molecule via a linker. The use of mAbs results in the delivery of the cytotoxic payload to only the targeted cell type, and because of this ADCs have shown promise as an …

What happens to Biosimilars being developed under 505b (2)?

Nitesh DaveĀ of Biocon joined us for World Biosimilar Congress USA 2016 to discuss what happens to biosimilars being developed under 505b (2). Download this presentation to understand more about: Key features of 505b (2) Key features of 351k (1, 2) Products approved under 505b (2) Path ahead for products under development and more! Get your copy here! If you’re interested …

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Jennifery Yearley of Merck joined us for Americas Antibody Congress 2016 to discuss ‘PD-L2 expression in human tumors’ In this presentation, learn about how PD-L2 expression in human tumors relates to Anti-PD-1 therapy in cancer. Download this presentation to understand more about: Programmed Cell Death 1 (PD-1) and Pembrolizumab PD-L2 Function as it relates to health & disease PD-L2 in …

Prevention of Recurrent C. difficile Infections (CDI) with Antitoxin Antibody Bezlotoxumab

Alex Therien of Merck joined us for Americas Antibody Congress 2016 to discuss ” prevention of recurrent CDIs with antitoxin antibody bezlotoxumab” . In this presentation learn about Clostridium difficile infections (CDI), why they are a growing concern, and how they can be prevented. Download this presentation to understand more about: The toxins of C. difficile: TcdA and TcdB CDI …

ADCs Targeting Embryonic Pluripotent Stem Cell Markers

Mike Schopperle of CureMeta joined us at Americas Antibody Congress 2016 to discuss ‘ADCs targeting embryoninc pluripotent stem cell markers’ Download this presentation to understand more about: Main focus in cancer drug development: oncogenes Common embryonic element present in all cancers CureMeta’s product engine to generate high specificity and high affinity antibodies to embryonic targets. and much more ! Get …

Xten protein polymer as clinically validated PEG alternative

Dr. Volker Schellenberger of Amunix joined us for Americas Antibody Congress 2016 to discuss ‘ Xten protein polymer as clincially validated PEG alternative’. In this presentation, learn about Xten protein polymer, and its use as high DAR drug linker and for tumor-protease triggered T cell activation . Download this presentation to understand more about: Biodegradable polymer with precisely-controlled structure Xten: …

Translating tumor antigens into a fully human antibody (HuMab-5B1) as a platform to diagnose and tread pancreatic cancer

Dr. Paul Maffuid of MabVax Therapeutics joined us for Americas Antibody Congress 2016 to discuss ‘translating tumor antigens into a fully human antibody as a platform to diagnose and treat pancreatic cancer ‘. In this presentation, learn about the evolution of MabVax HuMab Platform technology. Download this presentation to understand more about: HuMab Discovery Platform MabVax’s rich pipeline of potential …

Success Factors in the Design and Development of ADCs

Dr. John Lambert of ImmunoGen, Inc. joined us for Americas Antibody Congress 2016 to discuss ‘success factors in the design and development of ADCs ‘. In this presentation, learn about what factors affect the potential for success in ADC design and development. Download this presentation to understand more about: ADC (antibody) distribution Optimizing ADC design Development of new payload platform …

MS/MS Sequencing of Native Human Antibodies

Dr. Adrian Guthals of Mapp Biopharmaceuticals joined us for Americas Antibody Congress 2016 to discuss ‘MS/MS sequencing of native human antibodies’ Download this presentation to understand more about: Mass spectrometry Limitations of De Novo Peptide Sequencing Light chain variants and heavy chain variants and much more! Get your copy here! If you’re interested in learning more about native human antibodies, …

Human Monoclonal Antibodies against Emerging Viruses

Dimiter Dimitrov of National Cancer Institute, NIH joined us for Americas Antibody Congress 2016 to discuss ‘human monoclonal antibodies against emerging viruses’. In this presentation, learn about the correlation between human monoclonal antibodies and emerging viruses. Download this presentation to understand more about: Identification of mAbs by phage and yeast display from libraries of native human antibody fragments Libraries of …